ArticleNature medicine2017
The N
Open access · greenAbstract read
In one paragraph
Article in Nature medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 823 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
823citing papers in PubMed, 1 pooled it
44.0field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
823 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,300 citations in OpenAlex.
- DNA methylation in monozygotic twins discordant for acute lymphoblastic leukemia: a case report and systematic review.Clinical epigenetics · 2025Pooled it
- The cellular landscape of druggable RNA-binding proteins.Nature reviews. Drug discovery · 2026Review
- Direct and indirect regulation of fetal globin transcript by the RNA-binding protein IGF2BP1.Blood · 2026Article
- Characterization of METTL3/14-mediated m6A modification in human transcriptome using Nanopore direct RNA sequencing.PLoS genetics · 2026Article
- RBM15 in leukemogenesis: an emerging regulator at the interface of RNA biology and hematopoiesis.Trends in cancer · 2026Review
- Inhibiting METTL3 synergizes with Notch blockade to treat ESCC by targeting cancer stemness via m6A-JAG2.Journal of gastroenterology · 2026Article
- The N6-methyladenosine (mBritish journal of haematology · 2026Article
- RNA modifications as determinants of cancer cell death: from epitranscriptomic mechanisms to therapeutic targeting.Functional & integrative genomics · 2026Review
- PTBP1 controls oncogenic transcript processing and maintenance of acute myeloid leukemia.Leukemia · 2026Article
- RNA terminal uridylyl transferases are druggable vulnerabilities in AML but are dispensable for normal hematopoiesis.Science advances · 2026Article
- Dual regulation of the unfolded protein response by IGF2BP3 during ER stress.Genes & development · 2026Article
- m6A and NuRD complexes regulate monocytic differentiation and resistance to BCL2/BCL2L1 inhibitors in acute myeloid leukemia.Haematologica · 2026Article
- Review
- Interplay between N6-methyladenosine RNA methylation and protein lactylation: a novel crosstalk linking metabolism and epigenetic regulation in human diseases.Journal of translational medicine · 2026Review
- A non-enzymatic role for METTL3 as an Androgen Receptor co-regulator that promotes prostate cancer proliferation.bioRxiv : the preprint server for biology · 2026Article
- Role of methionine metabolism in cancer: recent advances in molecular mechanisms and therapeutic implications.Experimental hematology & oncology · 2026Review
- The new era of AML therapy: current standards and emerging targets.International journal of clinical oncology · 2026Review
- A novel biclustering algorithm for mining m6A co-methylation patterns based on beta-binomial distribution and data screening strategy.PLoS computational biology · 2026Article
- The Role of NMedComm · 2026Review
- mRedox biology · 2026Review
763 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
20 authors at 4 institutions in 1 country.
Ly P VuMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Brian F PickeringDepartment of Pharmacology, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Yuanming ChengMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Sara ZaccaraDepartment of Pharmacology, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Diu NguyenMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Gerard MinuesaMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Timothy ChouMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Arthur ChowMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Yogesh SaletoreDepartment of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Matthew MacKayDepartment of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Jessica SchulmanHematologic Oncology Tissue Bank, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Christopher FamulareCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Minal PatelCenter for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Virginia M KlimekMemorial Sloan Kettering Cancer Center, Department of Medicine, Leukemia Service, New York, New York, USA.
Francine E Garrett-BakelmanDepartment of Medicine and Department of Biochemistry and Molecular Genetics, University of Virginia, Charlottesville, Virginia, USA.
Ari MelnickDivision of Hematology and Medical Oncology, Department of Medicine and Department of Pharmacology, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Martin CarrollDivision of Hematology and Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, Cornell University, New York, New York, USA.
Samie R JaffreyDepartment of Pharmacology, Weill Cornell Medicine, Cornell University, New York, New York, USA.ORCID http://orcid.org/0000-0003-3615-6958
Michael G KharasMolecular Pharmacology Program, Center for Cell Engineering, Center for Stem Cell Biology, Center for Experimental Therapeutics, Center for Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York, USA.ORCID http://orcid.org/0000-0002-1165-6991
Memorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Pennsylvania · USUniversity of Virginia · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8MCANCER PHARMACOLOGYT32CA062948 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI LORRAINE J GUDAS · 1994 to 2026
$12.1MMechanisms of epitranscriptomic regulation in cancerR01CA186702 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI SAMIE R JAFFREY, Michael Kharas · 2014 to 2026
$8.0MUncovering the role for MSI2 network in hematopoietic stem cellsR01DK101989 · NIDDK · SLOAN-KETTERING INST CAN RESEARCH · PI Michael Kharas, Vijay Ganesh Sankaran · 2014 to 2026
$6.2MCharacterizing the MSI2 network in leukemiaR01CA193842 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI KHARAS, MICHAEL · 2015 to 2025
$4.1MThe mRNA methylation program in leukemiaF32CA221104 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI PICKERING, BRIAN FREDERICK · 2017 to 2017
$59kNCI NIH HHS F32 CA221104NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016672NCI NIH HHS R01 CA186702NCI NIH HHS R01 CA193842NCI NIH HHS T32 CA062948NIDDK NIH HHS R01 DK101989
Abstract
N
Indexed as
AdenosineBone Marrow CellsCell DifferentiationCells, CulturedClustered Regularly Interspaced Short Palindromic RepeatsHumansLeukemia, Myeloid, AcuteMethyltransferasesTumor Cells, CulturedAdenosineMethyltransferasesMETTL3 protein, humanN-methyladenosine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.